




# MEDICINAL PRODUCTS 2018

MYRIAD GENETICS INC  
Rank 15 of 49





RealRate

# MEDICINAL PRODUCTS 2018

## MYRIAD GENETICS INC Rank 15 of 49



The relative strengths and weaknesses of MYRIAD GENETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MYRIAD GENETICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 59% points. The greatest weakness of MYRIAD GENETICS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 82%, being 104% points above the market average of -22%.

Input Variable	Value in 1000 USD
Assets, Current	317,100
Assets, Non-Current	48,500
General and Administrative Expense	621,600
Goodwill	807,700
Liabilities, Current	217,500
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	4,200
Other Expenses	47,300
Other Liabilities	229,100
Other Net Income	-6,500
Other Revenues	771,400
Property, Plant and Equipment, Net	51,100
Research and Development	74,400

Output Variable	Value in 1000 USD
Liabilities	446,600
Assets	1,224,400
Expenses	743,300
Revenues	771,400
Stockholders Equity	777,800
Net Income	21,600
Comprehensive Net Income	23,700
Economic Capital Ratio	82%